Table 4 Treatment-related adverse events: safety analysis (n = 74)
From: Real-world data of anamorelin in advanced gastrointestinal cancer patients with cancer cachexia
Event | No. (%) | |
|---|---|---|
All Grades | Grade 3–4 | |
All | 40 (54.1) | 3 (4.0) |
Hyperglycemia | 10 (13.5) | 2 (2.7) |
Fatigue | 9 (12.2) | 1 (1.3) |
Nausea | 5 (6.7) | 0 (0.0) |
Stomach pain | 4 (5.3) | 0 (0.0) |
Diarrhea | 3 (4.0) | 0 (0.0) |
Edema | 3 (4.0) | 0 (0.0) |
Vomiting | 2 (2.7) | 0 (0.0) |
Abnormal ECG | 2 (2.7) | 0 (0.0) |
Hyperhidrosis | 1 (1.3) | 0 (0.0) |
Hypertension | 1 (1.3) | 0 (0.0) |